BioNTech SE (BNTX)
BioNTech lowers full-year revenue outlook on COVID-19 seasonality, inventory write-downs
German drugmaker BioNTech on Monday lowered its guidance for full-year revenue, citing COVID-19 uptake and price levels, inventory write-downs and Pfizer charges.
BioNTech to Report Q3 Earnings: Is a Beat in the Cards?
On BNTX's third-quarter 2024 earnings call, investors' focus is likely to be on the updates related to its oncology pipeline.
BioNTech's Oncology Gamble: High Stakes, Big Potential
BioNTech's oncology assets, including BNT327/PM8002, show promising results, with a notable 39.3% ORR in PD-L1-negative EGFR-mutated NSCLC patients. BioNTech's stock has risen by 24% since March, outperforming the S&P 500, driven by optimism in their oncology pipeline. Despite a partial FDA hold on BNT316/ONC-392 for NSCLC, other trials and treatments remain unaffected, signaling potential for resolution.
BioNTech (BNTX) Presents at Innovation Series: AI Day
BioNTech SE (NASDAQ:BNTX ) Company Conference Call October 1, 2024 9:00 AM ET Company Participants Karim Beguir - Chief Executive Officer, InstaDeep Uğur Şahin - Chief Executive Officer, BioNTech Ryan Richardson - Chief Strategy Officer, BioNTech Nacef Labidi - Head of Infrastructure, InstaDeep Alex Laterre - Head of Research, InstaDeep Alex Graves - Research Scientist, InstaDeep Bora Guloglu - Research Scientist, InstaDeep Julia Gimbernat - Product Manager, InstaDeep Arnu Pretorius - Research Scientist, InstaDeep Youssef Ben Dhieb - Senior ML Engineer, InstaDeep Thomas Pierrot - Research Scientist, InstaDeep Maren Lang - Senior Director, Bioinformatics R&D, BioNTech Marie Lopez - Research Engineer Team Lead, InstaDeep Daniel Rothenberg - Associate Director, Proteomics, BioNTech Michael Rooney - Director, Computational Biology, BioNTech Nicolas Lopez Carranza - Head of BioAI, InstaDeep Hippolyte Jacomet - Research Engineer, InstaDeep Sven Coutandin - Director, Global R&D Automation, BioNTech David Drakard - Senior Research Engineer, InstaDeep Michael Dahms - Director, Digitization R&D Labs, BioNTech Conference Call Participants Sam Fazeli - Bloomberg Intelligence Harry - Time Magazine Ian Johnston - Financial Times Unidentified Speaker - Karim Beguir Hi everyone. Welcome to AI Day.
BioNTech Is More Than a Covid-19 Stock. It's Having a Great September.
Recently BioNTech has been boosted a wave of enthusiasm over another company's cancer drug, which has turned the biopharma industry upside down.
How BioNTech, Up 25% Over Four Days, Is Riding Summit's Coattails To A Recovery
BioNTech stock has climbed 25% over four days as the German biotech rides a round of cancer treatment success from Summit Therapeutics.
BioNTech (BNTX) Stock Jumps 5.8%: Will It Continue to Soar?
BioNTech (BNTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
BioNTech's Low Valuation, Many Shots On Goal Make It A Buy
BioNTech shares surged 13% after Summit Therapeutics reported positive data on ivonescimab, a bispecific antibody similar to BioNTech's PM8002. BioNTech's PM8002 antibody is similar to Summit's ivonescimab. Despite declining Covid-19 vaccine revenue and safety concerns about those shot, BioNTech's low valuation and promising pipeline make it a buy for risk-tolerant, long-term investors.
Lung cancer patient is first in UK to receive experimental vaccine
A lung cancer patient has become the first in the UK to receive a new experimental vaccine to help his body fight the disease.
BioNTech says FDA lifts partial hold on its cancer drug trial
BioNTech on Monday said the U.S. Food and Drug Administration (FDA) has lifted a partial clinical hold on an early stage study of its experimental cancer drug.
BioNTech Q2 Earnings Review: No Needle-Moving Catalysts Despite Oncology Promise
BioNTech SE reported Q2 2024 earnings yesterday, with a significant decrease in revenues from Comirnaty compared to previous years. The company reaffirmed guidance for 2024, for revenues of $2.7bn — $3.4bn, but is expecting a loss-making year due to increased costs. The cash position remains healthy at nearly $20bn, which helps to support a $19.5bn market cap valuation at the present times.
BioNTech SE (BNTX) Q2 2024 Earnings Call Transcript
BioNTech SE (NASDAQ:BNTX ) Q2 2024 Earnings Conference Call August 5, 2024 8:00 AM ET Company Participants Victoria Meissner - Vice President, Strategy & Investor Relations Ugur Sahin - Chief Executive Officer & Co-Founder Özlem Türeci - Chief Medical Officer & Co-Founder Jens Holstein - Chief Financial Officer Ryan Richardson - Chief Strategy Officer Conference Call Participants Daina Graybosch - Leerink Partners Yaron Werber - TD Cowen Tazeen Ahmad - Bank of America Securities Etzer Darout - BMO Capital Markets Yifeng Liu - HSBC Bank Plc Jessica Fye - JPMorgan Chase Cory Kasimov - Evercore ISI Chris Shibutani - Goldman Sachs Simon Baker - Redburn Atlantic Eliana Merle - UBS John Newman - Canaccord Genuity Manos Mastorakis - Deutsche Bank Operator Welcome to BioNTech's Second Quarter 2024 Earnings Call. I would like to hand the call over to Dr. Victoria Meissner, Vice President of Strategy and Investor Relations.
